Norah Conway

Norah Conway joined Catalyst as Vice President of Project Management in May 2020. In this role, Ms. Conway is responsible for all project management aspects of Catalyst’s pre-clinical and clinical portfolio. Ms. Conway brings 20+ years of experience as a drug development professional managing global multi-disciplinary project teams. Her experience was gained through international leadership positions with Bayer in Regulatory Affairs and Program Management and most recently as Executive Director Program and Portfolio Management at Ultragenyx, where she led a rare disease program for X-linked hypophosphatemia, through licensure and launch in multiple regions.

Ms. Conway’s career experience encompasses biological and small molecule products; research phase through late-stage clinical development; regulatory submissions and approvals; launch and life cycle management as well as development collaborations. She has led multiple development programs in a broad range of therapeutic areas including haemophilia, sickle cell disease, cardiovascular, women’s health, oncology and HIV. In addition, she has had extensive engagement with Regulators in the USA (FDA) and Europe, as well as Japan and other international regulatory bodies, which has informed her strategic approach to Program Management.

Ms. Conway earned her Master’s in Pharmacy degree at the University of Pretoria, Faculty of Medicine, and graduated as a pharmacist at Pretoria College of Pharmacy. She also holds a Certificate in Project Management (PMP) from the Project Management Institute.